Amneal Pharmaceuticals, Inc. (AMRX), Friday announced financial outlook for the fiscal year 2025.
The company sees revenue in the range of $3.0 billion to $3.1 billion for the full year 2025.
Analysts, on average, estimate revenue of $2.92 billion for the same period.
The company projects adjusted earnings of $0.65 to $0.70 per share for the year.
Analysts, on average, expect earnings of $0.71 per share for the same year.
In the pre-market hours, Amneal's stock is trading at $8.60, up 2.63 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com